Wedbush Securities Inc buys $3,098,979 stake in Illumina (ILMN)

Illumina (ILMN) : Wedbush Securities Inc scooped up 3,075 additional shares in Illumina during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 2, 2016. The investment management firm now holds a total of 18,776 shares of Illumina which is valued at $3,098,979.Illumina makes up approximately 0.51% of Wedbush Securities Inc’s portfolio.

Other Hedge Funds, Including , Ipswich Investment Management sold out all of its stake in ILMN during the most recent quarter. The investment firm sold 550 shares of ILMN which is valued $90,778.Concert Wealth Management boosted its stake in ILMN in the latest quarter, The investment management firm added 105 additional shares and now holds a total of 1,684 shares of Illumina which is valued at $280,133. Illumina makes up approx 0.04% of Concert Wealth Management’s portfolio.Achievement Holdings boosted its stake in ILMN in the latest quarter, The investment management firm added 12,200 additional shares and now holds a total of 14,050 shares of Illumina which is valued at $2,279,613. Illumina makes up approx 0.29% of Achievement Holdings’s portfolio.British Columbia Investment Management Corp reduced its stake in ILMN by selling 919 shares or 1.18% in the most recent quarter. The Hedge Fund company now holds 76,733 shares of ILMN which is valued at $10,838,536. Illumina makes up approx 0.09% of British Columbia Investment Management Corp’s portfolio.

Illumina closed down -0.07 points or -0.04% at $166.46 with 10,59,246 shares getting traded on Monday. Post opening the session at $167.17, the shares hit an intraday low of $165.721 and an intraday high of $167.875 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Illumina reported $0.71 EPS for the quarter, missing the analyst consensus estimate by $ -0.03 based on the information available during the earnings call on May 3, 2016. Analyst had a consensus of $0.74. The company had revenue of $571.80 million for the quarter, compared to analysts expectations of $580.44 million. The company’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.91 EPS.

Many Wall Street Analysts have commented on Illumina. Company shares were Reiterated by Mizuho on Jul 27, 2016 to “Neutral”, Firm has raised the Price Target to $ 148 from a previous price target of $138 .Shares were Downgraded by Morgan Stanley on Jul 5, 2016 to ” Underweight” and Lowered the Price Target to $ 110 from a previous price target of $130 .Illumina was Initiated by CL King to “Buy” on Jun 22, 2016.

Illumina Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms reagent kits and scanning equipment. Its customers include genomic research centers academic institutions government laboratories hospitals and reference laboratories pharmaceutical biotechnology agrigenomics commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research including de novo sequencing genetic variation analysis epigenetics and targeted screening among others. It also provides products and services for other life sciences applied markets such as agrigenomics. It also offers Clarity Run Manager Clarity LIMS Silver and Clarity LIMS Gold.

Leave a Reply

Illumina - Is it time to Sell?

Top Brokerage Firms are advising their investors on Illumina. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.